Division of Thoracic and Cardiovascular Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Niigata, 951-8510, Japan.
Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Gen Thorac Cardiovasc Surg. 2022 Oct;70(10):835-841. doi: 10.1007/s11748-022-01809-3. Epub 2022 Mar 25.
Complete atrioventricular septal defect with tetralogy of Fallot is a rare and complex heart disease. This study aimed to describe contemporary management approaches for this heart disease and the outcomes.
Data were obtained from 46 domestic institutions in the Japan Cardiovascular Database (2011-2018). Patients with a fundamental diagnosis of complete atrioventricular septal defect with tetralogy of Fallot, without other complex heart diseases, were included. The primary outcome was operative mortality (30-day or in-hospital mortality).
A total of 119 patients underwent initial surgery for a complete atrioventricular septal defect with tetralogy of Fallot during this study period. Primary repair was performed in 40 (34%) patients (primary repair group), and palliative procedure was performed in 79 (66%) patients as part of a planned staged approach (staged group). Forty institutions (87%) experienced at least one case of staged repair. No institution experienced more than or equal to two cases/year on average during the study period. Overall, 11 operative mortalities occurred (9.2%). Operative mortality rates in the primary and staged groups were comparable (p = 0.5). Preoperative catecholamine use, repeat palliative surgeries, and emergency admission were significant risk factors for operative mortality in multivariate analysis (odds ratio, 95% confidence interval: 8.58, [0-0.11]; 12.65, [1.28-125.15]; 8.64, [1.87-39.32, respectively]).
Staged approach for complete atrioventricular septal defect with tetralogy of Fallot was the preferred option. The outcomes of this complex disease were favorable for patients in centers with low cases of complete atrioventricular septal defect with tetralogy of Fallot.
完全性房室间隔缺损合并法洛四联症是一种罕见且复杂的心脏病。本研究旨在描述这种心脏病的当代治疗方法和结果。
数据来自日本心血管数据库的 46 家国内机构(2011-2018 年)。纳入的患者基本诊断为完全性房室间隔缺损合并法洛四联症,无其他复杂心脏病。主要结局是手术死亡率(30 天或住院死亡率)。
在本研究期间,共有 119 例完全性房室间隔缺损合并法洛四联症患者接受了初始手术。40 例(34%)患者行一期修复(一期修复组),79 例(66%)患者行姑息性手术,作为计划分期治疗的一部分(分期组)。40 家机构(87%)至少有 1 例分期修复。在研究期间,没有任何一家机构平均每年有超过或等于 2 例。总的来说,11 例患者发生手术死亡(9.2%)。一期修复组和分期修复组的手术死亡率相当(p=0.5)。多变量分析显示,术前使用儿茶酚胺、重复姑息性手术和急诊入院是手术死亡的显著危险因素(比值比,95%置信区间:8.58,[0-0.11];12.65,[1.28-125.15];8.64,[1.87-39.32])。
分期治疗完全性房室间隔缺损合并法洛四联症是首选方法。对于完全性房室间隔缺损合并法洛四联症病例较少的中心的患者,这种复杂疾病的结局是有利的。